- Conditions
- Diabetic Macular Edema
- Interventions
- 0.3 mg ranibizumab, Targeted Pan Retinal Photocoagulation
- Drug · Procedure
- Lead sponsor
- David M. Brown, M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 3
- States / cities
- Houston, Texas • Katy, Texas • The Woodlands, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 251
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Diabetic Foot Ulcer
- Interventions
- SnapshotNIR, Kent Imaging
- Device
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Diabetic Retinopathy
- Interventions
- Octreotide Acetate in Microspheres, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Technosphere®/Insulin
- Drug
- Lead sponsor
- Mannkind Corporation
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Insulin Resistance, Postmenopause
- Interventions
- metformin, leuprolide injection, placebo pill, placebo injection
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 50 Years to 79 Years · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Painful Diabetic Peripheral Neuropathy
- Interventions
- pregabalin, placebo
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 55
- States / cities
- Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 38 more
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Drug
- Lead sponsor
- Retina Consultants of Orange County
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Fullerton, California
- Conditions
- Diabetic Foot Ulcer
- Interventions
- AutoloGel, Usual and Customary Care
- Device · Other
- Lead sponsor
- Cytomedix
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Hattiesburg, Mississippi
- Conditions
- Symptomatic Neurogenic Orthostatic Hypotension (NOH), Non-diabetic Neuropathy, Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency
- Interventions
- Placebo, Droxidopa
- Drug
- Lead sponsor
- Chelsea Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 14
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 11 more
- Conditions
- Diabetic Nephropathy
- Interventions
- SPP301
- Drug
- Lead sponsor
- Speedel Pharma Ltd.
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 2,364 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Greenville, North Carolina
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Charles C Wykoff, PhD, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 4
- States / cities
- Houston, Texas • Katy, Texas • Kingwood, Texas + 1 more
- Conditions
- Retinopathy, Diabetic
- Interventions
- Aflibercept Injection, Sham injection
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Diabetic Retinopathy
- Interventions
- Fenofibrate, Placebo
- Drug · Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 563 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 66
- States / cities
- Glendale, California • Huntington Beach, California • Loma Linda, California + 55 more
- Conditions
- Hyperglycemia
- Interventions
- Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine)
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Non-diabetic Chronic Kidney Disease
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Diabetic Foot Ulcer (DFU)
- Interventions
- Xcell Amnio Matrix, Standard of Care (SOC)
- Biological · Drug
- Lead sponsor
- New Horizon Medical Solutions
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Fresno, California • San Diego, California • Dallas, Texas
- Conditions
- Inflammatory Response
- Interventions
- MetFORMIN Hydrochloride ER, Placebo
- Drug
- Lead sponsor
- Brian Zuckerbraun
- Other
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Weight Loss, Obesity
- Interventions
- Byetta (exenatide), Weight loss, Metabolic Chamber, Placebo
- Drug · Behavioral · Other
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2016
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Diabetic Retinopathy
- Interventions
- RO7663498
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Diabetic Retinopathy
- Interventions
- BI 764524, Sham control of BI 764524
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 13
- States / cities
- Dothan, Alabama • Beverly Hills, California • Palo Alto, California + 10 more
- Conditions
- Neuropathic Diabetic Foot Ulcers
- Interventions
- Placebo, UTTR1147A
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 10
- States / cities
- Mesa, Arizona • San Francisco, California • Durango, Colorado + 7 more
- Conditions
- Chronic Kidney Disease
- Interventions
- AZD4248, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Glendale, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- muraglitazar
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,752 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 108
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 105 more
- Conditions
- Diabetic Foot Ulcers
- Interventions
- Aurix
- Device
- Lead sponsor
- Nuo Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 760 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 20
- States / cities
- Arcadia, California • Montebello, California • Visalia, California + 14 more